Jinwu Financial News | Cinda Biotech (01801) announced that the new drug Cinpirac (tolecimab injection, anti-PCSK9 monoclonal antibody) and the new indications of Nellick (olevatinib, BCR-ABL inhibitor) were successfully included in the new “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2024)” (“National Health Insurance Catalogue”). The new version of the National Health Insurance Catalogue will be officially implemented on January 1, 2025.
This time, the new drug Cinpirac (tolecimab injection) was included in the national medical insurance catalogue to treat adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia. As Cinda Biologics's first product in the field of cardiovascular and metabolic (“CVM”) diseases, Cipilac (tolecimab injection) provides a flexible treatment plan with three treatment intervals of 2/4/6 weeks. While significantly reducing low density cholesterol (“LDL-C”) levels while taking into account the significant decrease in lipoprotein a (“Lp (a)”), LDL-C decreased by nearly 70% and Lp (a) by nearly 50%. Cinpirac (tolecimab injection) successfully became the first locally developed PCSK9 inhibitor included in China's national health insurance, bringing high-quality treatment options to the clinical management of blood lipids in China, and will also improve the overall quality of life of patients with hypercholesterolemia.
At the same time, the indications in the original catalog of Nellik (olevatinib) were successfully renewed, and the new indications were successfully included in the national health insurance catalogue through a simple renewal procedure. Currently, medical insurance payments cover: adult patients with chronic myeloid leukemia (“CML”) chronic phase (“-CP”) or accelerated phase (“-AP”) with T315I mutation; and adult CML-CP patients resistant and/or intolerant to first-generation and second-generation tyrosine kinase inhibitors (“TKI”). Nellik (olevatinib) is the first third-generation BCRABL inhibitor approved for marketing by China's National Drug Administration (“NMPA”). Cinda Biotech and Yasheng Pharmaceuticals (06855) are jointly responsible for commercialization promotion of Nellick (Orebatinib) in China.
